HK1202817A1 - 通過施用絲氨酸蛋白酶抑制劑治療或預防流感病毒感染的方法 - Google Patents

通過施用絲氨酸蛋白酶抑制劑治療或預防流感病毒感染的方法

Info

Publication number
HK1202817A1
HK1202817A1 HK15103529.7A HK15103529A HK1202817A1 HK 1202817 A1 HK1202817 A1 HK 1202817A1 HK 15103529 A HK15103529 A HK 15103529A HK 1202817 A1 HK1202817 A1 HK 1202817A1
Authority
HK
Hong Kong
Prior art keywords
administering
treating
methods
influenza virus
protease inhibitor
Prior art date
Application number
HK15103529.7A
Other languages
English (en)
Inventor
Ngambo Lisa A Purcell
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1202817A1 publication Critical patent/HK1202817A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK15103529.7A 2012-04-16 2015-04-10 通過施用絲氨酸蛋白酶抑制劑治療或預防流感病毒感染的方法 HK1202817A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624519P 2012-04-16 2012-04-16
US201361759469P 2013-02-01 2013-02-01
PCT/US2013/036522 WO2013158516A1 (en) 2012-04-16 2013-04-15 Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor

Publications (1)

Publication Number Publication Date
HK1202817A1 true HK1202817A1 (zh) 2015-10-09

Family

ID=48184523

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15103529.7A HK1202817A1 (zh) 2012-04-16 2015-04-10 通過施用絲氨酸蛋白酶抑制劑治療或預防流感病毒感染的方法

Country Status (14)

Country Link
US (1) US9498529B2 (zh)
EP (2) EP3536342A1 (zh)
JP (2) JP6446355B2 (zh)
KR (1) KR20150008383A (zh)
CN (1) CN104244978A (zh)
AU (2) AU2013249577A1 (zh)
BR (1) BR112014025339A8 (zh)
CA (2) CA2869010A1 (zh)
HK (1) HK1202817A1 (zh)
MX (1) MX2014012285A (zh)
NZ (1) NZ631105A (zh)
SG (1) SG11201405163RA (zh)
WO (1) WO2013158516A1 (zh)
ZA (1) ZA201406194B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3422845T3 (da) 2016-02-29 2021-08-30 Regeneron Pharma Gnavere med et humaniseret tmprss-gen
KR101693243B1 (ko) * 2016-06-15 2017-01-05 재단법인 한국파스퇴르연구소 인플루엔자 바이러스의 복제에 관여하는 신규 인간 유전자 및 이의 용도
ES2864529T3 (es) * 2018-01-26 2021-10-14 Regeneron Pharma Anticuerpos y fragmentos de unión a antígeno anti-TMPRSS2
AU2021219671A1 (en) 2020-02-10 2022-07-14 Regeneron Pharmaceuticals, Inc. Anti-Tmprss2 Antibodies and Antigen-Binding Fragments
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
WO2021195119A1 (en) * 2020-03-24 2021-09-30 Corcept Therapeutics Incorporated Methods of reducing the risk of, severity of, and treating coronavirus infections
EP3964207A1 (en) 2020-09-02 2022-03-09 Christian-Albrechts-Universität zu Kiel Antiviral pharmaceutical composition for topical administration
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4839999A (en) * 1998-06-29 2000-01-17 Myriad Genetics, Inc. Tmprss2 is a tumor suppressor
WO2004097358A2 (en) 2003-05-02 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
ZA200705980B (en) * 2005-01-07 2009-01-28 Lexicon Pharmaceuticals Inc Monoclonal antibodies against angiopoietin-like protein 4 (ANGPTL4)
US20070191322A1 (en) 2006-02-01 2007-08-16 Savage Paul B Cationic Steroid Microbial Compositions and Methods of Use
JP2008247864A (ja) * 2007-03-30 2008-10-16 Univ Of Tokushima モザイクセリンプロテアーゼ、ｍｓｐとその用途
JP2008308438A (ja) * 2007-06-14 2008-12-25 Mitsubishi Tanabe Pharma Corp 新規なインフルエンザ治療および／または予防薬
ES2441973T3 (es) 2009-06-22 2014-02-07 Borealis Ag Artículo del interior del automóvil con olor reducido
DK2814849T3 (da) * 2012-02-15 2020-03-09 Cydex Pharmaceuticals Inc Fremgangsmåde til fremstilling af cyclodextrin-derivater

Also Published As

Publication number Publication date
EP3536342A1 (en) 2019-09-11
NZ631105A (en) 2016-09-30
CA2869010A1 (en) 2013-10-24
BR112014025339A2 (pt) 2013-10-24
BR112014025339A8 (pt) 2018-01-16
SG11201405163RA (en) 2014-09-26
WO2013158516A1 (en) 2013-10-24
CN104244978A (zh) 2014-12-24
AU2013249577A1 (en) 2014-10-02
KR20150008383A (ko) 2015-01-22
MX2014012285A (es) 2015-04-13
US9498529B2 (en) 2016-11-22
ZA201406194B (en) 2016-08-31
EP2838558A1 (en) 2015-02-25
JP6446355B2 (ja) 2018-12-26
JP2015516975A (ja) 2015-06-18
AU2018200265B2 (en) 2019-07-18
JP2018048169A (ja) 2018-03-29
CA3219083A1 (en) 2013-10-24
AU2018200265A1 (en) 2018-02-01
US20130273070A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
HK1202817A1 (zh) 通過施用絲氨酸蛋白酶抑制劑治療或預防流感病毒感染的方法
HK1257685A1 (zh) 作為絲氨酸蛋白酶抑制劑的多取代芳族化合物
ZA201306720B (en) Hepatitis c virus inhibitors
HK1212905A1 (zh) 用於防止登革熱病毒感染的疫苗組合物
GB201213087D0 (en) Inhibition of HIV-1 infection
IL229270B (en) Hepatitis c virus inhibitors
EP2768517A4 (en) HEPATITIS C-VIRUS HEMMER
HK1206986A1 (zh) 流行性感冒病毒感染癥的預防‧治療劑
ZA201309356B (en) Hepatitis c virus inhibitors
HK1212332A1 (zh) 丙型肝炎病毒抑制劑
EP2771332A4 (en) HIV PROTEASE INHIBITORS
HK1202820A1 (zh) 用於治療由包膜病毒引致的疾病的唾液酸粘附素抑制劑
HK1213816A1 (zh) 治療 型肝炎病毒感染的醫藥組合物
KR101501876B9 (ko) 자일리톨을 유효성분으로 함유하는 인플루엔자 바이러스 감염증 예방 또는 치료용 조성물
ZA201307019B (en) Compositions for preventing and/or treating and infection by an hiv-1 virus
EP2712317A4 (en) PREVENTION OF INFECTIONS
PL2850075T3 (pl) Związki piperazyno-piperydyny jako inhibitory wirusa zapalenia wątroby typu c
EP2749287A4 (en) INHIBITOR OF INFLUENZA VIRUS INFECTION
HK1205680A1 (zh) 用於治療丙型肝炎病毒的藥劑
EP2694654A4 (en) PEPTIDES OF PROTEASE CLEAVAGE SITE AS VACCINE AGAINST HIV
AU2012905097A0 (en) Agents and methods for inhibiting virus infection
TH1201004783B (th) สารประกอบซึ่งต้านการติดเชื้อ